TriSalus Life Sciences (NASDAQ:TLSIW) Trading Down 10.1% – What’s Next?

Posted by ABMN Staff on May 28th, 2026

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) shares fell 10.1% during mid-day trading on Wednesday . The company traded as low as $0.4551 and last traded at $0.6630. 3,015 shares traded hands during trading, a decline of 35% from the average session volume of 4,616 shares. The stock had previously closed at $0.7375.

TriSalus Life Sciences Trading Down 10.1%

The stock has a fifty day moving average of $0.94 and a 200-day moving average of $1.20.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of large investors have recently bought and sold shares of the business. Aristeia Capital L.L.C. purchased a new position in TriSalus Life Sciences during the 4th quarter valued at $43,000. Fort Baker Capital Management LP purchased a new position in TriSalus Life Sciences during the 4th quarter valued at $44,000. Cerity Partners LLC purchased a new position in TriSalus Life Sciences during the 4th quarter valued at $1,374,000. Finally, Citadel Advisors LLC raised its position in TriSalus Life Sciences by 439.0% during the 3rd quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock valued at $199,000 after purchasing an additional 103,336 shares in the last quarter.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.